STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines

Abstract

IntroductionThymic malignancies are rare tumors with few therapeutic options. The STYLE trial was aimed to evaluate activity and safety of sunitinib in advanced or recurrent type B3 thymoma (T) and thymic carcinoma (TC). MethodsIn this multicenter, Simon 2 stages, phase 2 trial, patients with pretreated T or TC were enrolled in two cohorts and assessed separately. Sunitinib was administered 50 mg daily for 4 weeks, followed by a 2-week rest period (schedule 4/2), until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR). Progression-free survival, overall survival, disease control rate and safety were secondary endpoints. ResultsFrom March 2017 to January 2022, 12 patients with T and 32 patients with TC were enrolled. At stage 1, ORR was 0% (90% confidence interval [CI]: 0.0–22.1) in T and 16.7% (90% CI: 3.1–43.8) in TC, so the T cohort was closed. At stage 2, the primary endpoint was met for TC with ORR of 21.7% (90% CI: 9.0%–40.4%). In the intention-to-treat analysis, disease control rate was 91.7% (95% CI: 61.5%–99.8%) in Ts and 89.3% (95% CI: 71.8%–97.7%) in TCs. Median progression-free survival was 7.7 months (95% CI: 2.4–45.5) in Ts and 8.8 months (95% CI: 5.3–11.1) in TCs; median overall survival was 47.9 months (95% CI: 4.5–not reached) in Ts and 27.8 months (95% CI: 13.2–53.2) in TCs. Adverse events occurred in 91.7% Ts and 93.5% TCs. Grade 3 or greater treatment-related adverse events were reported in 25.0% Ts and 51.6% TCs. ConclusionsThis trial confirms the activity of sunitinib in patients with TC, supporting its use as a second-line treatment, albeit with potential toxicity that requires dose adjustment.